Authors' objectives
This is the protocol for a review and there is no abstract. The objectives are as follows: General objective: To assess the overall effects of treatment with beta-3 adrenergic receptor agonists in adults with OAB by doing a systematic review and meta-analysis of all available RCTs. Specific objectives: To compare the efficacy and safety of beta-3 adrenergic receptor agonists as an intervention for adult patients with OAB through assessing its effect on the symptoms of urgency, incontinence, nocturia and frequency by making the following comparisons: beta-3 adrenergic receptor agonists versus placebo or no treatment; beta-3 adrenergic receptor agonists versus conservative physical treatments (e.g. bladder training, urge suppression, pelvic floor muscle training); beta-3 adrenergic receptor agonists versus anticholinergic/antimuscarinic drugs (e.g. tolterodine, darifenacin, solifenacin, fesoterodine, oxybutynin, propiverine); beta-3 adrenergic receptor agonists versus intravesical Onabotulinumtoxin A injection; beta-3 adrenergic receptor agonists versus electrical stimulation (non-invasive or implanted); one dose regimen of a beta-3 adrenergic receptor agonist versus another; one frequency of administration of a beta-3 adrenergic receptor agonist versus another; one route of administration of a beta-3 adrenergic receptor agonist versus another; one type of beta-3 adrenergic receptor agonist versus another. beta-3 adrenergic receptor agonists versus placebo or no treatment; beta-3 adrenergic receptor agonists versus conservative physical treatments (e.g. bladder training, urge suppression, pelvic floor muscle training); beta-3 adrenergic receptor agonists versus anticholinergic/antimuscarinic drugs (e.g. tolterodine, darifenacin, solifenacin, fesoterodine, oxybutynin, propiverine); beta-3 adrenergic receptor agonists versus intravesical Onabotulinumtoxin A injection; beta-3 adrenergic receptor agonists versus electrical stimulation (non-invasive or implanted); one dose regimen of a beta-3 adrenergic receptor agonist versus another; one frequency of administration of a beta-3 adrenergic receptor agonist versus another; one route of administration of a beta-3 adrenergic receptor agonist versus another; one type of beta-3 adrenergic receptor agonist versus another.

Bibliographic details

AccessionNumber
1000011593

Date abstract record published
26/03/2015

Record Status
This is an abstract for a Cochrane review